Significant heterogeneity in the geographical distribution of diffuse grade II/III gliomas in France
- PMID: 25151505
- DOI: 10.1007/s11060-014-1585-0
Significant heterogeneity in the geographical distribution of diffuse grade II/III gliomas in France
Abstract
Diffuse WHO grade II and III gliomas (DGII/IIIG) are rare tumors, with few specific epidemiological studies. We aimed at describing the geographical distribution of a homogeneous series of histologically confirmed DGII/IIIG, over a four-year period (2006-2009), at a national level. The methodology is based on a multidisciplinary national network already established by the French Brain Tumor DataBase and data collected directly from every neuropathology department. Personal home addresses were collected for confirmed cases. For each region, the incidence of DGII/IIIG was analyzed and standardized on the age and sex distribution of the French population. The number of patients with newly diagnosed, histologically confirmed DGII/IIIG was 4,790. The overall crude rate was 19.4/10(6). To enable international comparisons, standardized rates were calculated as follows: 19.8/10(6), 18.8/10(6) and 16.0/10(6) (reference population, Europe, US and world, respectively). The geographical distribution by region showed significant differences, with higher incidence rates in Northeast and central parts of France. This work is the first studying the geographical distribution of a pure series of DGII/IIIG at a national level. It demonstrates significant heterogeneity in the distribution, and raises the question of the role of environmental and/or genetic risk(s) factor(s) for DGII/IIIG.
Similar articles
-
Epidemiology for primary brain tumors: a nationwide population-based study.J Neurooncol. 2017 Feb;131(3):525-546. doi: 10.1007/s11060-016-2318-3. Epub 2016 Nov 16. J Neurooncol. 2017. PMID: 27853959
-
An epidemiology report for primary central nervous system tumors in adolescents and young adults: a nationwide population-based study in France, 2008-2013.Neuro Oncol. 2020 Jun 9;22(6):851-863. doi: 10.1093/neuonc/noz227. Neuro Oncol. 2020. PMID: 31796950 Free PMC article.
-
Epidemiology of malignant gliomas in Iran: first report of Iranian National Population-based Cancer Registry, 2009-2017.J Neurosurg. 2024 Jul 5;142(1):197-205. doi: 10.3171/2024.4.JNS2470. Print 2025 Jan 1. J Neurosurg. 2024. PMID: 38968626
-
Italian cancer figures--Report 2015: The burden of rare cancers in Italy.Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120. doi: 10.19191/EP16.1S2.P001.035. Epidemiol Prev. 2016. PMID: 26951748
-
Descriptive epidemiology of cerebral gliomas in France.Cancer. 1997 Mar 15;79(6):1195-202. doi: 10.1002/(sici)1097-0142(19970315)79:6<1195::aid-cncr19>3.0.co;2-v. Cancer. 1997. PMID: 9070498
Cited by
-
Towards an advanced cell-based in vitro glioma model system.AIMS Genet. 2018 Mar 19;5(2):91-112. doi: 10.3934/genet.2018.2.91. eCollection 2018. AIMS Genet. 2018. PMID: 31435515 Free PMC article. Review.
-
Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study.J Neurooncol. 2019 Mar;142(1):91-101. doi: 10.1007/s11060-018-03065-z. Epub 2018 Dec 6. J Neurooncol. 2019. PMID: 30523606 Free PMC article.
-
Epidemiology for primary brain tumors: a nationwide population-based study.J Neurooncol. 2017 Feb;131(3):525-546. doi: 10.1007/s11060-016-2318-3. Epub 2016 Nov 16. J Neurooncol. 2017. PMID: 27853959
-
Bevacizumab in recurrent WHO grades II-III glioma.Front Oncol. 2023 Jul 18;13:1212714. doi: 10.3389/fonc.2023.1212714. eCollection 2023. Front Oncol. 2023. PMID: 37534252 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical